Ausgabe 6/2016
Inhalt (6 Artikel)
“No patient left behind”: an alternative to “the War on Cancer” metaphor
Bryan T. Oronsky, Corey A. Carter, Arnold L. Oronsky, Michael E. Salacz, Tony Reid
Alterations in inflammatory biomarkers and energy intake in cancer cachexia: a prospective study in patients with inoperable pancreatic cancer
Asta Bye, Nima Wesseltoft-Rao, Per Ole Iversen, Grete Skjegstad, Kirsten B. Holven, Stine Ulven, Marianne J. Hjermstad
Rap2B promotes cell proliferation, migration and invasion in prostate cancer
Jiehui Di, Huan Cao, Juangjuan Tang, Zheng Lu, Keyu Gao, Zhesi Zhu, Junnian Zheng
ERAS protocol in laparoscopic surgery for colonic versus rectal carcinoma: are there differences in short-term outcomes?
Michał Pędziwiatr, Magdalena Pisarska, Michał Kisielewski, Piotr Major, Anna Mydlowska, Mateusz Rubinkiewicz, Marek Winiarski, Andrzej Budzyński
Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib
Hiroyuki Kobayashi, Kazuhiro Sato, Takenori Niioka, Masahide Takeda, Yuji Okuda, Mariko Asano, Hiroshi Ito, Masatomo Miura
Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?
Mahmoud Abbas, Sandra Steffens, Maria Bellut, Jan U. Becker, Anika Großhennig, Hendrik Eggers, Gerd Wegener, Markus A. Kuczyk, Hans H. Kreipe, Viktor Grünwald, Andres J. Schrader, Philipp Ivanyi